Please assess the completion status of the following clinical trial:

Trial Title: Lentiviral-mediated Gene Therapy of Fanconi Anemia Patients Subtype A

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients diagnosed with Fanconi Anemia complementation group A (FA-A)~* Minimum age 1 year~* Maximum age 21 years~* Lansky Index\> 60%.~* Informed consent in accordance with current legal regulations.~* Number of cells to be transduced: At least 3x10\^5 purified CD34+ / kg body weight.~* Negative result in the urine pregnancy test at the baseline visit for women of childbearing age, who should be committed to using an effective contraceptive method during the period of study participation.~Exclusion Criteria:~* Patients with an human leukocyte antigen (HLA) identical family donor.~* Evidence of myelodysplastic syndrome or leukemia, or cytogenetic abnormalities predicting the same in bone marrow aspirates. In this case, the studies carried out two months in advance of the patient's entry into the clinical trial will be considered valid.~* Evidence that the patient to be infused has signs of somatic mosaicism, with hematologic improvement.~* Any illness or concomitant process that in the opinion of the investigator incapacitates the subject for their participation in the study.~* Pre-existing sensory or motor impairment\> = grade 2 according to the National Cancer Institute (NCl) criteria.~* Pregnant or lactating women.

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- Autologous CD34+ cells transducted with PGK-FANCA-Wpre * (Type: EXPERIMENTAL): CD34 + cells from patients with Fanconi subtype A (FA-A) transduced ex vivo with lentiviral vector carrying the gene FANCA, PGK-FANCA-Wpre\*The product to be infused consist of a suspension of transduced CD34\^+ cells.

Based on this trial design, predict the completion outcome and termination type (if applicable).